首页> 美国卫生研究院文献>Journal of Korean Medical Science >Surfactant Therapy for Neonatal Respiratory Distress Syndrome: A Review of Korean Experiences over 17 Years
【2h】

Surfactant Therapy for Neonatal Respiratory Distress Syndrome: A Review of Korean Experiences over 17 Years

机译:新生儿呼吸窘迫综合征的表面活性剂治疗:韩国17年经验的回顾。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We undertook a multi-hospital collective study to evaluate outcomes of neonatal respiratory distress syndrome (RDS) patients treated with pulmonary surfactant (PS) over 17 yr in Korea (Group I; 1990/91, Group II; 1996, Group III; 2002, and Group IV; 2007). There were 60 neonates in Group I (16 hospitals), 1,179 in Group II (64), 1,595 in Group III (62), and 1,921 in Group IV (57). We adopted Bomsel's classification to evaluate initial chest radiographic findings, categorized RDS severities, and classified response types to PS therapy. Almost all cases were treated using a single dose in Groups I and II, but 19.5% received multiple-dose therapy in Group IV. In Group IV, Bomsel's stages III and IV composed 62.9% and initial severities of mild, moderate, and severe RDS were 23.0%, 42.0%, and 35.0%. More infants showed good response in Groups II, III, and IV than in Group I (71.7%, 66.8%, and 69.2% vs. 58.3%). Complications and mortality rate were lower in Group IV than in Groups I, II, and III (mortality rate: 14.3% vs. 40.0%, 30.0%, and 18.7%). We conclude that PS therapy in neonates with RDS had a remarkable impact on improving clinical course and outcomes over 17 yr in Korea.
机译:我们进行了一项多院集体研究,以评估在韩国接受肺表面活性剂(PS)治疗超过17年的新生儿呼吸窘迫综合征(RDS)患者的结局(I组; 1990/91,II组; 1996年,III组; 2002年,和第IV组; 2007年)。第一组(16所医院)中有60例新生儿,第二组(64例)中有1179例,第三组(62例)中有1,595例,第四组(57例)中有1,921例。我们采用Bomsel分类法评估了最初的胸部X线影像学发现,对RDS严重程度进行分类以及对PS治疗的反应类型进行了分类。在I和II组中,几乎所有病例均采用单剂量治疗,但在IV组中,有19.5%的患者接受了多剂量治疗。在IV组中,Bomsel的III期和IV期占62.9%,轻度,中度和重度RDS的初始严重度分别为23.0%,42.0%和35.0%。与第一组相比,第二,第三和第四组的婴儿表现出良好的反应(71.7%,66.8%和69.2%,而58.3%)。第四组的并发症和死亡率低于第一,第二和第三组(死亡率:14.3%比40.0%,30.0%和18.7%)。我们得出的结论是,在韩国,RDS新生儿的PS疗法对改善其临床病程和结局具有显着影响,超过17年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号